Masimo to Present in the 24th Annual Needham Virtual Healthcare Conference
Masimo (NASDAQ: MASI) has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference. The company's management will present on Wednesday, April 9, 2025 at 2:15 p.m. Eastern time.
A live webcast of the presentation will be accessible through the company's website at www.masimo.com, with a replay option available after the live event.
Masimo (NASDAQ: MASI) ha annunciato la sua partecipazione alla prossima 24ª Conferenza Virtuale Annuale sulla Salute di Needham. La direzione dell'azienda presenterà mercoledì 9 aprile 2025 alle 14:15 ora orientale.
Una diretta streaming della presentazione sarà accessibile attraverso il sito web dell'azienda all'indirizzo www.masimo.com, con un'opzione di replay disponibile dopo l'evento dal vivo.
Masimo (NASDAQ: MASI) ha anunciado su participación en la próxima 24ª Conferencia Virtual Anual de Salud de Needham. La dirección de la empresa presentará el miércoles 9 de abril de 2025 a las 2:15 p.m. hora del Este.
Una transmisión en vivo de la presentación estará disponible a través del sitio web de la empresa en www.masimo.com, con una opción de repetición disponible después del evento en vivo.
Masimo (NASDAQ: MASI)는 다가오는 제24회 니드햄 가상 의료 컨퍼런스에 참가한다고 발표했습니다. 회사 경영진은 2025년 4월 9일 수요일 동부 표준시 오후 2시 15분에 발표할 예정입니다.
발표의 생중계는 회사 웹사이트 www.masimo.com을 통해 접속할 수 있으며, 생중계 후에는 다시 보기 옵션이 제공됩니다.
Masimo (NASDAQ: MASI) a annoncé sa participation à la prochaine 24e Conférence Virtuelle Annuelle de Santé de Needham. La direction de l'entreprise présentera le mercredi 9 avril 2025 à 14h15, heure de l'Est.
Une diffusion en direct de la présentation sera accessible via le site web de l'entreprise à www.masimo.com, avec une option de rediffusion disponible après l'événement en direct.
Masimo (NASDAQ: MASI) hat seine Teilnahme an der bevorstehenden 24. Virtuellen Jahrestagung für Gesundheitswesen von Needham bekannt gegeben. Das Management des Unternehmens wird am Mittwoch, den 9. April 2025 um 14:15 Uhr Eastern Time präsentieren.
Ein Live-Stream der Präsentation wird über die Unternehmenswebsite www.masimo.com zugänglich sein, mit einer Wiederholungsoption, die nach der Live-Veranstaltung verfügbar ist.
- None.
- None.
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2 improve CCHD screening in newborns,3 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.4-7 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,8 and is the primary pulse oximetry at all 10 top
RPVi has not received FDA 510(k) clearance and is not available for sale in
References
- Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar.
- Estimate: Masimo data on file.
- https://www.newsweek.com/rankings/worlds-best-hospitals-2024/united-states
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI and ORI are trademarks or registered trademarks of Masimo Corporation
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402480122/en/
Investor Contact: Eli Kammerman
(949) 297-7077
ekammerman@masimo.com
Media Contact: Evan Lamb
(949) 396-3376
elamb@masimo.com
Source: Masimo